Xanodyne newest pharm co. to cancel IPO
Xanodyne joins a growing number of biopharmaceutical and life science companies calling it quits on going public, at least for now. The Newport, Ky.-based firm withdrew its filing on Friday, citing poor market conditions — it had been waiting since November. Not that the company is really hurting. It’s raised about $232 million to date, and announced successful results in phase three trials of its lead drug candidate in August.
In the past, it has received backing from Apax Partners, Essex Woodlands Health Ventures, HealthCare Ventures VI and Blue Chip Capital. Phenomix, a San Diego company specializing in diabetes treatments, pulled its IPO plans last week. As VentureBeat reported before, only four health care companies have managed to go public so far this year. Because biotech and pharmaceuticals is such a high risk area for public investors, the window for IPOs may stay closed for a while yet.
Xanodyne’s top drug is used to treat menorrhagia, a condition that causes a dangerously heavy menstrual cycle in women.
Next Story: Transoma brings in $5M for heart diagnostics
Previous Story: HipLogic unveils virtual platform for mobile phones
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.